Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA)
CRC-SCA is a natural history study funded by the National Ataxia Foundation (NAF). The study enrolls individuals who have a confirmed diagnosis of SCA 1, 2, 3, 6, 7, 8, 10, 27B, or RFC1/CANVAS. Participants enrolled in CRC-SCA have extensive longitudinal clinical data available, with a cross-sectional biospecimen collection added in 2020. In 2023, CRC-SCA expanded to include follow-up biospecimen collections for a subset of participants.
Study Participants
The study is currently recruiting individuals in the United States and Canada with SCA27B or RFC1 Ataxia/CANVAS to participate in this study. Recruitment of individuals with other forms of ataxia is currently paused. However, longitudinal collections from existing participants with other SCA types are still being conducted.
Enrollment
Enrollment in CRC-SCA overlaps significantly with the Clinical Trial Readiness Study for SCA1 and SCA3 (READISCA), which is also banked with BioSEND.
Available Data
CLINICAL: performance, observational, and self-reported assessments of motor, cognitive, and functional staging
GENETIC: SCA mutation/CAG repeat length
Available Biospecimens
Plasma, serum, CSF, whole blood, and DNA.
CRC-SCA is funded by The National Ataxia Foundation. We kindly acknowledge the patients involved in this consortium for their generous contributions to this research.